Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.
--------
Question: Former Minister of Health Oly Ilunga was taken into custody, police said in a statement Saturday. Ilunga resigned in July to protest President Felix Tshisekedi’s decision to take over the management of the response to the world’s second deadliest Ebola outbreak, which is ongoing now in eastern Congo, from Ilunga. As he resigned, Ilunga deplored the lack of cooperation between him, the president and the prime minister in response to the deadly Ebola outbreak. Police said Saturday that Ilunga had been arrested less than a month ago for misdemeanor offenses involving the mishandling of funds and he was released. He has since made plans to travel to the neighboring Republic of Congo, they said, adding he was taken into custody to make sure he would not avoid legal proceedings. Congo’s National Ebola Response Committee released the latest Ebola numbers Friday after a discussion in Goma by the Catholic Church and the Anglican Church about efforts to help stem the spread of Ebola in communities. A mistrust of health workers and widespread security issues still threaten the fight against the Ebola outbreak in a region where armed groups have fought for decades over the mineral-rich land. The committee reported there were 3,002 confirmed Ebola cases with 1,974 confirmed deaths. The World Health Organization said Friday they recorded 40 new cases of Ebola — the lowest weekly incidence of Ebola since March 2019 — but said it was unclear if this positive trend would continue.

Answer: Congo police detain ex-health minister in Ebola funds probe.


Question: The company’s forecast implies a potential $3 billion upgrade to the consensus estimate from analysts and marks an attempt to call a bottom to a sales decline driven by the loss of exclusivity on several top-selling medicines. Britain’s second-biggest drugmaker is already suffering from generic competition to its antipsychotic Seroquel, while its Nexium treatment for excess stomach acid loses U.S. patent cover this year. Top-selling Crestor, for high cholesterol, faces competition from cheap copycat drugs in 2016. The patent expiries leave AstraZeneca’s sales on a near-term downward spiral at a time when most of its rivals have put their biggest patent losses behind them. Shares in the group rose 1.6 percent by 1215 GMT on the more upbeat outlook, against a 0.3 percent decline for the European healthcare sector. Chief Executive Pascal Soriot, who has been leading the company for a little more than a year, will set out the new revenue guidance in a presentation at the J.P. Morgan Healthcare conference in San Francisco later on Tuesday. The company will then give a more detailed update on its progress in full-year results on February 6. The consensus of analyst forecasts compiled by Thomson Reuters is for 2017 revenue of $22.5 billion, down from the $25.8 billion estimated for 2013. However, a number of the 2017 forecasts pre-date the diabetes drug deal struck last month that is already expected to add some $1 billion to $2 billion to annual revenue. Citigroup analyst Andrew Baum said the positive medium-term outlook reinforced his “more constructive thesis” for the stock, adding that he expects Soriot to strike more earnings-boosting deals this year. Panmure Gordon’s Savvas Neophytou remains more wary, pointing out that Soriot’s predecessor, David Brennan, had made a similar attempt to talk up AstraZeneca’s longer-term prospects. “In our view, management is stepping onto thin ice with this same sort of guidance,” Neophytou said, pointing out the previous management’s failure to hit its forecasts. AstraZeneca has become more confident about its revenue outlook after the $4 billion deal last month to buy Bristol-Myers Squibb’s share of a diabetes joint venture. The acquisition is expected to complete in the first quarter of 2014 and will boost sales immediately. Mark Clark of Deutsche Bank said this was set to lift analysts’ revenue forecasts significantly, suggesting that a more realistic “adjusted consensus” for 2017 was around $24.3 billion rather than $22.5 billion. Soriot has been striking a number of bolt-on deals to refill the company’s thin pipeline of new medicines and accelerating in-house research programs. The group now has 11 new-drug programs in late-stage Phase III testing, almost double the number a year ago, and 27 in Phase II. Hopes are particularly high for its cancer research, where it has started trials for immunotherapy combination treatments for which the first results are anticipated in 2014/15. AstraZeneca is behind the likes of Bristol-Myers, Roche and Merck & Co in the race to develop immunotherapies - a hot new area of cancer research - but it is betting on combination treatments to help it to catch up. Immunotherapy, which harnesses the body’s immune system to fight cancer, has shown great promise in clinical trials and analysts believe that the treatments may extend patients’ lives significantly and generate tens of billions of dollars in annual sales.

Answer: Drugmaker AstraZeneca forecasts faster return to growth.


Question: "Ed Stafford of Leicestershire, England walks in between trees as he walks through the Amazon jungle in Brazil in this undated handout photo. Former British army captain Stafford became on Monday the first known person to walk from the origin of the Amazon river, the world's second-longest river, to its mouth, after withstanding ""50,000"" mosquito bites, scorpion attacks and skin disease in his 859 day odyssey. REUTERS/Handout Ed Stafford, a 34-year-old from Leicestershire, England, dived into the Atlantic Ocean after taking 859 days to walk the length of the world’s second-longest river, starting at the peak of Mount Mismi in Peru in April 2008. “It’s just phenomenal to be here at the end of the journey after 2-1/2 years slogging our way through the jungle,” he told Reuters after arriving at the beach about 90 miles northeast of the Brazilian city of Belem. “It was really difficult to envisage how this was going to feel and I’m completely overwhelmed.”   Stafford briefly collapsed from exhaustion with only 52 miles of the 6,000-mile journey to go, passing out by the roadside after breaking out in a rash. “I feel slightly humbled that my system just decided to shut down so close to the finish,” he wrote on his blog at www.walkingtheamazon.com. Stafford has aimed to use the walk to raise awareness about the threats to the Amazon rain forest and its people, using a portable satellite video to blog about his trek. He had planned to complete the walk in about a year, but the journey was prolonged by floods that forced him to walk a roundabout route that was 2,000 miles longer than the 4,000-mile (6,400-km) length of the Amazon, which is exceeded in length only by Africa’s Nile river. He began the journey with fellow British adventurer Luke Collyer, but the pair had a falling out early in the trek and Stafford continued alone. He was joined in July 2008 by a Peruvian forestry worker, Gadiel Cho Sanchez Rivera, who pledged to walk with him for five days and has been with him on the walk ever since. A statement from Stafford’s media team said that the Briton had been: “wrongly accused of murder on two separate occasions, been imprisoned, had concrete stuffed in his mouth by hostile tribes people, been chased by Ashaninka Indians with bows and arrows, been stung by hundreds of wasps and watched as his guide ‘Cho’ removed a botfly from Ed’s head with superglue and a tree spine.”   It said he had endured “50,000” mosquito bites, lived on a diet of piranha fish, rice and beans, and dodged a variety of snakes, electric eels, scorpions, and ants, as well as contracting a skin-disfiguring disease. Famed British explorer Sir Ranulph Fiennes was quoted as saying in the statement that Stafford’s feat was “truly extraordinary.”   “No one has ever done this before and the pundits considered the route impossible,” he said."

Answer:
British man becomes first to walk Amazon length.